Hormone Receptor Positive Tumor Recruiting Phase 1 / 2 Trials for Vistusertib (DB11925)

IndicationStatusPhase
DBCOND0075370 (Hormone Receptor Positive Tumor)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02730923Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)Treatment